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Abstract: The role of NKG2D-expressing Natural Killer (NK) cells in tumor immune
surveillance is now well established. Nevertheless, tumor progression occurs despite tumor immune surveillance leading to cancer persistence in immune competent hosts. STAT3 plays a pivotal role both in oncogenic functions and immune suppression. In this study, we investigated the role of STAT3 in suppressing NK cell-mediated immunosurveillance. Using a colorectal cancer cell line (HT29) that is poorly able to activate NK, we neutralized STAT3 with pharmacological inhibitors or siRNA and found that this led to an increase of NK degranulation and interferon-gamma production in a TGF-β1 independent manner. Exposure to NKG2D neutralizing antibodies partially restored STAT3 activity, suggesting that it prevented NKG2D-mediated NK cell activation. On this basis, we investigated the expression of NKG2D ligands after STAT3 activation in HT29, mesenchymal stem cells and activated lymphocytes. The NK cell recognition receptor MICA was upregulated following STAT3 neutralization and a direct interaction between STAT3 and the MICA promoter was identified. Since crosstalk between DNA damage repair and NKG2D ligand expression has been demonstrated, we assessed the influence of STAT3 on MICA expression under conditions of genotoxic stress. We found that STAT3 negatively regulated MICA expression after irradiation or heat shock, including in lymphocytes activated by CD3/CD28 ligation.
Together, our findings reveal a novel role for STAT3 in NK cell immunosurveillance by modulating the MICA expression in cancer cells.
Introduction
The immune system can detect and suppress emerging tumors (1) . In addition to their role in pathogen immunity, Natural Killer cells (NK) have been implicated in tumor surveillance in both mice and human models (1) (2) (3) (4) (5) (6) . Among NK activating receptors, Natural Killer Group 2, member D receptor (NKG2D), is a C-type lectin-like transmembrane glycoprotein recognizing self-molecules (referred as NKG2D ligands; NKG2DLs) that emerged as a pivotal signaling pathway supporting cancer immune surveillance. Indeed, transfected tumor cell lines expressing NKG2DLs are rejected in vivo in an NKG2D-dependent manner (7, 8) .
Recently, generation of NKG2D-deficient mice confirmed the critical role of these stimulatory NK receptors in immune surveillance of spontaneous prostate cancer and lymphoma models (9) . Contrary to prostate cancer arising in NKG2D-deficient mice, tumor cells isolated from fast-growing carcinoma in control mice (and not in smaller late-arising tumors) lacked NKG2DLs, suggesting a NKG2D-dependent immune editing (9) and supporting the hypothesis that oncogenic pathways associated with cancer progression might negatively regulate NKG2DLs.
MHC class I chain related A and B (MICA and MICB) or ULBP proteins (7, 10, 11) are NKG2DLs, weakly expressed on normal cells and up-regulated in cancers (12) (13) (14) (15) (16) .
Nonetheless, molecular mechanisms leading to NKG2DLs regulation are poorly defined.
The enhanced incidence of colorectal cancer (CRC) in patients affected by inflammatory bowel disease (IBD) had established chronic inflammation as a corner stone mechanism in tumor suppressor checkpoint subversion (17, 18) . Particularly, interleukin 23 (IL-23) was shown to increase tumor incidence in mice (19) and to decrease cancer immune surveillance (20) . STAT3 is a transcription factor activated in IBD (21) (22) (23) and directly involved both in intestinal inflammation and cancer progression (24, 25) .
In the present study, we aimed to investigate the role of STAT3 activation in the regulation of NKG2DLs expression and recognition of tumor cells by NK. We showed that STAT3 ablation in tumor cells modulates NKG2D-mediated NK cell activation. STAT3 directly interacts with MICA promoter to repress MICA transcription. These results shed light on the negative regulation exerted by STAT3 on MICA expression in different cell types submitted to DNA damage or cellular stress. 
Materials and Methods
Reagents
The following antibodies were used: anti-human MICA (BZ-26) (Diaclone, Besançon, France); anti-human CD107a (LAMP-1) (H4A3), isotype PE (MOPC-21) (BD Biosciences, Le Pont de Clay, France); anti-MICA-PE (2C10), MICB (9847-1), ULBP1 (Z-9), ULBP2 (F16), ULBP3 (2F9), TGF-β1 (C-16) (Santa Cruz Biotechnology, Heidelberg, Germany), anti-human STAT3 (79D7) and phospho-Stat3 (Tyr705) (3E2) (Cell Signaling, Beverly, USA), neutralizing anti-MICA (clone 159227, RnDsystems, Minneapolis, USA). STA-21, a selective inhibitor of STAT3 was purchased from BIOMOL International (Plymouth, USA).
Oncostatin M (Peprotech, France) was used in some experiments. The TGF-β1 receptor inhibitor SB-431542 (Tocris Biosciences, Bristol, UK) was used in some experiments.
Dynabeads® Human T-Expander CD3⁄CD28 (Invitrogen, Cergy-Pontoise, France) were used for stimulation of PBL.
Cell lines and primary cells cultures.
HT29 (ATCC, HTB-38), SW620 (ATCC, CCL-227), Colo320 (ATCC, CCL-220), K562 (ATCC, CCL-243), MDA-MB231 (ATCC, HTB26), U87 (ATCC, HTB-14) and 293T (DSMZ, ACC-635) cells were verified by morphology, tested for mycoplasma and conserved in master cell bank upon reception. Cells were never used above passage 10. The stroma cell line SV56 was established as previously described (26) . Cells were maintained in either RPMI 1640 (K562 and SV56) or DMEM (HT29, SW620 and Colo320) medium (Lonza, Paris, France) supplemented with 10% Fetal Calf Serum (FCS) (Invitrogen, CergyPontoise, France). NK were purified from healthy donor peripheral blood mononuclear cells (PBMC) using a negative magnetic selection (Stem Cell, Vancouver, Canada). The Human STAT3C in pBABE vector was provided by Dr J Bromberg (27) . pGL3-MICA-pro vector was previously described and kindly given by Dr. Jack D. Bui (28) . 
Site-directed Mutagenesis
Real Time-quantitative PCR (RT-qPCR).
Total RNA were extracted using Kit RNeasy mini (Qiagen, Courtaboeuf, France) and reverse transcribed using random hexamers and Moloney murine leukemia virus reverse transcriptase (Life Technologies, Rockville, MD, USA). Duplicate samples were subjected to RT-qPCR. mRNA were quantified using primers listed below : MICA (Hs00792193_m1) (Applied Biosystems). ABL mRNA from each sample was quantified as an endogenous control.
Relative mRNA expression was calculated using the Delta-Delta-Ct method and untreated cells were used as calibrator. 
Luciferase Assay
ELISA
Detection of IFN-γ was done using commercial ELISA kits (Diaclone, France). The sensitivity of the human IFN-γ kit was 4.7 pg/mL. Detection of MICA was done using ELISA kits (Diaclone, France). The sensitivity of the human MICA ELISA kit was 123 pg/ml. All concentrations are expressed as mean ± SEM of triplicates.
NK Degranulation assay
NK cells were activated for 24h with IL-2 (1000 UI/ml) and then cocultured in presence of target cells for 4 hours at 10:1 E:T ratio. Degranulation of NK cells was analyzed by flow cytometry analysis of CD107a expression as previously described (29) . 
Statistical analysis
Results are expressed as the mean plus or minus the standard error of mean. Group comparisons were performed using Student's t-test. Differences were considered significant at p < 0.05. 
Results
Role of STAT3 in colon cancer cell line susceptibility to NK cells
The implication of STAT3 in chronic intestinal inflammation and cancer oncogenesis prompted us to investigate the ability of different colon cancer cell lines to activate NK (30) (31) (32) (33) . For this purpose, NK were purified from peripheral blood lymphocytes of normal volunteers and incubated with colon cancer cell lines or with the NK-sensitive K562 cell line for 24 hours. These preliminary experiments indicated that HT29 is a weak activator of NK cell functions in vitro, compared to Colo320, SW620 and K562 ( Figure 1A and 1B). The higher expression of STAT3 in HT29 compared to K562, Colo320 or SW620 ( Figure 1C) prompted us to investigate the precise role of STAT3 in the recognition of HT29 by NK.
In order to confirm the influence of STAT3 in colorectal cancer models, we generated STAT3 deficient cell lines using a lentivirus-mediated gene transfer to deliver a specifically designed siRNA for STAT3 into HT29 and to produce a stable cell line (HT29 siRNA-STAT3 ). Western blot analysis confirmed a reduced expression of STAT3 in the knock-down cell line HT29
siRNA-STAT3 ( Figure 2A) . Moreover, the level of phospo-STAT3 was also decreased in HT29
siRNA-STAT3 ( Figure 2B ).
The next set of experiments was dedicated to assess if the presence of STAT3 influences HT29 recognition by NK. Freshly purified NK were co-cultured for 24h with HT29, HT29 siRNA-CTRL or HT29 siRNA-STAT3 and harvested supernatants were then assessed for IFN-γ production ( Figure 2C ). HT29 siRNA-STAT3 triggered a significantly increased secretion of IFN-γ by NK compared to HT29 siRNA-CTRL or HT29 (1276 ± 82 pg/ml versus 510 ± 2 pg/ml and 462 ± 38 pg/ml). To further study STAT3 implication on NK functions, we assessed NK degranulation according to STAT3 expression in HT29. Direct CD107a staining was 
STAT3 inhibition of HT29 recognition by NK involves a TGF-β1 independent mechanism.
NK functions result from the integration of activating and inhibitory signaling related to different ligands recognized on target cells. Transforming growth factor beta isoform 1 (TGF-β1), a cytokine produced by HT-29 (34), has been previously characterized as a major inhibitory pathway limiting tumor cell recognition by NK (35) . Moreover, we and others have shown that STAT3 can directly trigger TGF-β1 transcription (36, 37) . Therefore, the expression of TGF-β1 in HT29 siRNA-CTRL and HT29 siRNA-STAT3 was analyzed by flow cytometry ( Figure 3A ). We noticed a decreased expression of TGF-β1 in HT29 siRNA-STAT3 compared to Figure 1) . As shown previously, we observed a significant increase in IFN-γ production when we compared HT29
siRNA-STAT3 to HT29
siRNA-CTRL
. TGF-β1
inhibition resulted in a weak up-regulation of NK activation. In contrast, we could observe that STAT3 neutralization mediated by siRNA improved NK recognition of HT29 even when TGF-β1 signaling was blocked ( Figure 3C ). These results suggest that TGF-β1 and STAT3 act independently to repress NK recognition of HT29. As NK activation is known to be the result of an integration of positive and negative signaling pathways following target cell recognition, it is plausible that in the absence of the TGF-β1-mediated inhibitory signaling, STAT3 specific inhibition promotes the expression of NK-activating ligands on HT29.
STAT3 knock-down restores NKG2DLs expression
Raulet DH et al. demonstrated an increased tumor incidence in NKG2D -/-mice (9). As a consequence, avoidance of this specific NKG2D/NKG2DLs pathway is a hallmark of many malignancies against NK immunity (28, 39, 40) . Consequently, we choose to determine whether STAT3 was implicated in NKG2D-based tumor cell recognition. To clarify this point, previous experiments were reproduced in the presence of neutralizing anti-NKG2D or IgG control antibodies. NK were pre-treated for 30 min at 37°C with blocking antibodies and then co-cultured with HT29 siRNA-CTRL or HT29 siRNA-STAT3 for 24h and harvested supernatants
were assessed for IFN-γ production. As shown in Figure 4A , left panel, IFN-γ production by NK in the co-culture with HT29 siRNA-STAT3 was significantly decreased in the presence of NKG2D neutralization while not affected by control antibodies. Of note, NKG2D blockade Figure   5D ).
STAT3 directly interacts with specific binding sites in MICA promoter
In order to exert its action as a transcriptional factor, STAT3 forms a cytoplasm homodimer, translocates into the nucleus and interacts with functional transcription factor binding sites observations. We used the predictive software MatInspector for TFBSs and found a significant match (5'-TTCTTCCAGGACAGACAA-3') for a more recently discovered sequence (core nucleotide denoted in capitals: TTCCNGG) (43) . Complementary analyses were realized on MICB and ULBPs promoter sequences as well. We obtained specific sequences for MICB (3'-TTCCTTCCGGGACAGACAA-5') and ULBP2 (3'-CATCTTCCAGGCTCTCCTT-5') promoters while no specific matches were retrieved from ULBP1 and ULBP3 promoter investigations ( Supplementary Data 1 and 2 ). We initiated a ChIP assay to control whether STAT3 was indeed able to bind the TFBS given by 
Influence of STAT3 on MICA regulation by DNA damage pathways
DNA damage response pathway was reported to play a role in up-regulation of NKG2DLs and this molecular signaling is a possible candidate bridging cellular transformation and innate immune surveillance (16) . For this purpose, the role of STAT3 in NKG2DLs induction by DNA damage response or heat shock was investigated in mesenchymal stem cells and activated lymphocytes known to express MICA (45, 46) . The SV56 stroma cell line (26) was transduced with a retroviral vector containing a sequence for a modified and constitutive active form of STAT3 (STAT3C) or the empty vector (pBabe) and exposed to ionizing radiation or heat shock stress. STAT3 constitutive activation led to a down-regulation of MICA and prevented the induction of MICA following ionizing radiation or heat shock exposition ( Figure 7A ). 
Furthermore, ATM mediated DNA damage response pathway also induces MICA expression on activated T cell lymphocytes (46) . Since we and others have previously reported a STAT3 phosphorylation driven by CD28 costimulation in CD4+ lymphocytes (37, 47) , we next investigated the influence of STAT3 on MICA expression following CD3/CD28 mediated activation of T lymphocytes. For this purpose, T cell lymphocytes were purified, exposed or not to different STAT3 pharmacological inhibitors and activated by CD3/CD28 during 48h.
As shown in Figure 7B , pharmacological inhibition of STAT3 promoted higher level of MICA expression in T lymphocytes following CD3/CD28 stimulation ( Figure 7B ). These results confer to STAT3 a pivotal role in MICA regulation, both in cancer and non malignant cells.
Discussion
NKG2D is an activating receptor shared by NK and T cell lymphocytes, now identified as a pivotal mechanism to prevent the emergence of cancer cells arising following DNA-damage induction or spontaneous transformation (7, 9, 16) . In the present study, we investigated the role of STAT3, a transcription factor harboring both oncogenic and immunosuppressive functions (27, 37) , in NKG2DLs expression regulation.
In this study, we found that specific repression of STAT3 with RNA interference promoted the recognition of HT29 by NK. We demonstrated that this mechanism involves the activating receptor NKG2D (Figure 4) . We revealed an inverse correlation between STAT3 activation and expression of MICA. Finally, ChIP analyses and luciferase promoter assays have shown for the first time MICA as a target for STAT3 transcriptional regulation ( Figure 6 ).
The role of NKG2D in NK immunosurveillance has been well documented. NKG2D is involved in the prevention of cancer initiation (9) and control of tumor progression (8 Many studies revealed the IL-6/STAT3 signaling pathway to be critical for IBD development (51) . Then, it is plausible that STAT3 could be activated at the time of epithelial cell transformation or DNA-damage exposition and binds MICA promoter to prevent its expression and promote escape to NKG2D mediated immunosurveillance. 
